LncRNA Information
ID EL0556 Name H19 Aliases ASM; ASM1; BWS; D11S813E; LINC00008; NCRNA00008; WT2
Species Homo sapiens Chromosome 11 Start site 1995163
End site 2001470 Chain minus Exon NO. 6
Assembly Ensembl Release 89 Class lincRNA NCBI accession NR_131224, NR_131223, NR_002196
Ensembl ENSG00000130600 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
colorectal cancer a case-control study N/A N/A N/A N/A 27027436
gastric cancer AGS cells, knock out of H19 gastric cancer AGS cells down-regulated N/A H19 or miR-675 enhanced RUNX1 expression 26931432
osteoarthritis cDNA array and quantitative RT-PCR OA and normal knee cartilage up-regulated interaction LncRNA H19 acts as a metabolic correlate in cartilage and cultured chondrocytes, while the miR-675 may indirectly influence COL2A1 levels. H19 may not only be an attractive marker for cell anabolism but also a potential target to stimulate cartilage recovery 22527881
gallbladder cancer gallbladder cancer gallbladder cancer tissues and adjacent normal tissues up-regulated N/A The overexpression of H19 in GBC cells enhanced tumor invasion and promoted EMT 27073719
bladder cancer ISH etc. bladder cancer tissue etc. differential expression expression The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. 11193051 LncRNADisease Lnc2Cancer
gestational choriocarcinoma ISH etc. placenta tissue up-regulated expression Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. 8188082 LncRNADisease Lnc2Cancer
trophoblastic tumor ISH etc. placenta tissue up-regulated expression Prominent expression of H19 was found in placental site trophoblastic tumor and gestational choriocarcinoma. 8188082 LncRNADisease Lnc2Cancer
laryngeal squamous cell carcinoma knockdown LSCC patients up-regulated N/A The inhibition of LSCC progression induced by H19 knockdown required the activity 26872375
nasopharyngeal carcinoma knockdown NPC tissues up-regulated N/A H19 regulated EZH2 expression suppressing the activity of miR-630 27040767
hepatocelluar carcinoma microarray, qPCR etc. HCC tissue up-regulated expression We found that imbalances in levels of IGF2 and H19 transcripts were correlated with advanced tumor stage and poor outcome in HCC patients. 15736456 LncRNADisease Lnc2Cancer
gastric cancer microarray, qPCR etc. gastric cancer tissue, cell lines (GES-1, AGS, MGC-803, SGC-7901) up-regulated N/A As shown in Figure 2D, comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). 24063685 Lnc2Cancer
ovarian cancer microarray, qPCR etc. ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) down-regulated N/A The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. 24379988 Lnc2Cancer
gastric cardia adenocarcinoma microarray, qPCR etc. gastric cancer tissue up-regulated N/A H19 expression level was 4.97 to 13.58-fold higher in GCa samples than the mean level in paired non-cancerous tissues. Moreover, the expression levels of H19 were increased significantly in the tumors of patients with advanced clinical stage (p < 0.001) and larger tumor size ( p < 0.001). 24414129 Lnc2Cancer
gastric cancer microarray, qPCR etc. gastric cancer tissue, cell lines (HCG-27, SGC-7901) up-regulated expression H19 and HOTAIR displayed significantly higher levels and the up-regulation of HOTAIR was associated with lymphatic metastasis and poor differentiation. 26237576 Lnc2Cancer
hepatocelluar carcinoma microarray, qPCR, knockdown, ISH etc. cell lines (T24P, HepG2, Hep3B etc.) up-regulated N/A The H19 non-coding RNA is essential for human tumor growth. 17786216 LncRNADisease Lnc2Cancer
bladder cancer microarray, qPCR, knockdown, ISH etc. cell lines (T24P etc.) up-regulated N/A The H19 non-coding RNA is essential for human tumor growth. 17786216 LncRNADisease Lnc2Cancer
ovarian cancer microarray, qPCR, Western blot etc. cell lines (OVCAR-3, OV-90 and SK-OV-3) down-regulated interaction We find that overexpression of H1.3 decreases the growth rate and colony formation of OVCAR-3 cells. We identify histone H1.3 as a specific repressor for the noncoding oncogene H19. Overexpression of H1.3 suppresses H19 expression, and knockdown of H1.3 increases its expression in multiple ovarian epithelial cancer cell lines. Furthermore, we demonstrate that histone H1.3 overexpression leads to increased occupancy of H1.3 at the H19 regulator region encompassing the imprinting control region (ICR), concomitant with increased DNA methylation and reduced occupancy of the insulator protein CTCF at the ICR. Finally, we demonstrate that H1.3 overexpression and H19 knockdown synergistically decrease the growth rate of ovarian cancer cells 25205099 Lnc2Cancer
glioma microarray, qPCR, Western blot, knockdown, Luciferase reporter assay etc. glioma tissue, cell lines (U87, U251 etc.) up-regulated regulation Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. 24466011 LncRNADisease Lnc2Cancer
colorectal cancer Multivariate analyses 83 CRC patients up-regulated N/A overexpression of H19 promoted the proliferation of CRC cells; growth regulator 26989025
choricarcinoma N/A N/A N/A regulation Control of imprinting. Containing miRNA miR-675. 22996375 LncRNADisease
type 2 diabetes mellitus N/A muscle of human subjects with type-2 diabetes and insulin resistant rodents. down-regulated expression H19 is significantly decreased in muscle of human subjects with type-2 diabetes and insulin resistant rodents. This decrease leads to increased bioavailability of let-7, causing diminished expression of let-7 targets, which is recapitulated in vitro where H19 depletion results in impaired insulin signaling and decreased glucose uptake. 25399420
glioblastoma multiforme N/A GBM cell lines up-regulated N/A H19 in contributing to GBM malignancy 26983719
cardiac hypertrophy N/A normal and diseased hearts up-regulated N/A overexpression of H19 reduced cell size both at baseline and in response to PE; knockdown of H19 induced cardiomyocyte hypertroph 27084844
heart failure N/A normal and diseased hearts up-regulated N/A overexpression of H19 reduced cell size both at baseline and in response to PE; knockdown of H19 induced cardiomyocyte hypertroph 27084844
myeloproliferative disease polycythaemia vera N/A N/A N/A expression Expression of the imprinted tumour-suppressor gene H19 is tightly regulated during normal haematopoiesis and is reduced in haematopoietic precursors of patients with the myeloproliferative disease polycythaemia vera. 10640993 LncRNADisease
Marek's disease N/A N/A N/A mutation The mutant CVI/rpp38 was not only reactive with MAb H19 in IFA but also in immunoprecipitation. 10696440 LncRNADisease
congenital hyperinsulinism N/A N/A N/A expression In agreement with the loss of the maternal chromosome, the level of expression of a maternally expressed tumor suppressor gene, H19, was greatly reduced compared to the level of expression of the paternally expressed growth promoter gene, IGF2. 11395395 LncRNADisease
Beckwith-Wiedemann syndrome N/A N/A N/A epigenetics Mosaicism for 11p15 UPD and hypermethylation of the H19 gene in blood cells were associated with an increased risk of tumour. 11436121 LncRNADisease
melanoma N/A N/A N/A expression The study of 4 sensitive and 2 resistant cell lines allowed the identification of 4 genes (RCC1, IFI16, hox2 and h19) preferentially transcribed in sensitive ((IFN-alpha therapy) cells and 2 (SHB and PKC-zeta) preferentially expressed in resistant cells. 11437411 LncRNADisease
Beckwith-Wiedemann syndrome N/A N/A N/A epigenetics Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. 11813134 LncRNADisease
gestational trophoblastic diseases N/A N/A N/A expression LOI, deregulation of IGF2 promoters, and the altered expression levels of IGF2 and H19 genes might be associated with the progression of GTD. 12648595 LncRNADisease
chronic myeloproliferative disorders N/A N/A N/A expression Reduced expression of H19 in bone marrow cells from chronic myeloproliferative disorders. 12682647 LncRNADisease
biparental complete hydatidiform moles N/A N/A N/A epigenetics H19 is abnormally methylated on the maternal alleles in BiCHMs. 12783848 LncRNADisease
Beckwith-Wiedemann syndrome N/A N/A N/A mutation Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. 15314640 LncRNADisease
colon cancer N/A N/A N/A expression DT-A was preferentially expressed in liver metastases after being transfected with H19 or IGF2-P3 promoter-driven DT-A expression plasmids, causing a very significant inhibition of tumor growth as a result of its cytotoxic effect. 15521051 LncRNADisease
cancer N/A N/A N/A expression The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. 15618002 LncRNADisease
hyperhomocysteinemia N/A N/A N/A epigenetics The effect of hyperhomocysteinemia on H19 DMD methylation was tissue-specific. hyperhomocysteinemia produces tissue-specific changes in H19 DMD methylation and increased vascular expression of H19 in adult mice. 15899898 LncRNADisease
cancer N/A N/A N/A expression H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival. 16189152 LncRNADisease
Beckwith-Wiedemann syndrome N/A N/A N/A locus The H19 locus acts in vivo as a tumor suppressor. 18719115 LncRNADisease
Silver-Russell syndrome N/A N/A N/A mutation Epigenetic mutations of the imprinted IGF2-H19 domain in Silver-Russell syndrome 19066168 LncRNADisease
pre-eclampsia N/A N/A N/A mutation LOI of H19 can be identified in pre-eclamptic placentas and is associated with maternal blood pressures, which implies the involvement of H19 gene LOI in the pathogenesis of pre-eclampsia and its potential relationship with the severity of the disease. 19570415 LncRNADisease
melanoma N/A N/A N/A expression H19 RNA downregulation stimulated melanogenesis in melasma. 19968822 LncRNADisease
infertility N/A N/A N/A expression H19 expression was lower in the infertility group as compared to the control group. 20042264 LncRNADisease
growth restriction N/A N/A N/A epigenetics A loss of methylation at H19. 20104244 LncRNADisease
glioblastoma N/A N/A N/A expression Another study performed in CD133+ and CD133- glioblastoma derived primary cell lines revealed levels of H19 expression that were relatively high and low, respectively. 20380817 LncRNADisease
medulloblastoma N/A N/A N/A epigenetics A study of medulloblastomas and medulloblastoma cell lines showed partial loss of imprinting (LOI) and biallelic expression of H19. 20380817 LncRNADisease
meningioma N/A N/A N/A epigenetics An examination of meningiomas (World Health Organization grades I-III) demonstrated more robustly that the imprinting status of H19 is perturbed with LOI in a significant number of these tumors. 20380817 LncRNADisease
melanoma N/A N/A N/A mutation Although the IGF2 and H19 genotypes/haplotypes were not significantly associated with melanoma, two of the most severe cases (very early onset or multiple melanomas) showed to be heterozygous for both genes. 20483645 LncRNADisease
Wiedemann-Beckwith syndrome N/A N/A N/A epigenetics Genetic analyses of the patient's blood showed hypermethylation at the H19 locus on chromosome 11p. 21058226 LncRNADisease
Silver-Russell syndrome N/A N/A N/A epigenetics The major finding (~44%) is a hypomethylation of the imprinting control region 1 (ICR1) in 11p15.5 affecting the expression of H19 and IGF2. 4-10% of the patients carry a maternal UPD of chromosome 7 (UPD(7)mat). 21150838 LncRNADisease
liver cancer N/A N/A N/A epigenetics H19 ICR showed loss-of-imprinting in two steps and allelic histone marker signature during tumorigenesis showed similarity with ES cells. 21163252 LncRNADisease
Mullerian aplasia N/A N/A N/A epigenetics Methylation of H19 and its imprinted control region (H19 ICR1) in Mullerian aplasia. 21458801 LncRNADisease
colon cancer N/A N/A N/A N/A Regional therapy with DTA-H19 vector suppresses growth of colon adenocarcinoma metastases in the rat liver. 21874233 LncRNADisease
pheochromocytoma N/A N/A N/A mutation Tumor DNA from the index patient revealed loss of heterozygosity (LOH) at 11q23, causing loss of the wild-type paternal SDHD allele and LOH affecting maternal 11p15, including H19. 21937622 LncRNADisease
atherosclerosis N/A N/A N/A epigenetics The most pronounced differences of atherosclerotic plaques in DNA methylation levels were registered for a site which is located in CpG-island of imprinted gene H19. 21954592 LncRNADisease
breast cancer N/A N/A N/A mutation Different SNPs in LSP1 and H19 and in minor genes probably were associated with BC risk. 21996731 LncRNADisease
adrenocortical carcinomas N/A N/A N/A epigenetics This disease has been associated with structural abnormalities at the 11p15 locus, which harbors the IGF2 gene as well as the genes coding for insulin, H19, and p57kip2. 22019903 LncRNADisease
neural tube defects N/A N/A N/A epigenetics The methylation levels of H19 DMR1 in the NTD and control groups are 73.3%卤15.9 and 58.3%卤11.2, respectively. Hyper-methylation of the H19 DMR1 may be correlated with the occurrence of NTDs. 22234160 LncRNADisease
obesity N/A N/A N/A epigenetics Insulin-like Growth Factor 2/H19 Methylation at Birth and Risk of Overweight and Obesity in Children. 22341586 LncRNADisease
Wilms' tumor N/A N/A N/A epigenetics 37% of patients with Wilms' tumor were H19 epimutations. 22470196 LncRNADisease
bladder cancer N/A N/A N/A regulation Control of imprinting. Containing miRNA miR-675. 22996375 LncRNADisease
breast cancer N/A N/A N/A regulation Control of imprinting. Containing miRNA miR-675. 22996375 LncRNADisease
colon cancer N/A N/A N/A regulation Control of imprinting. Containing miRNA miR-675. 22996375 LncRNADisease
esophageal squamous cell carcinoma N/A N/A N/A regulation Control of imprinting. Containing miRNA miR-675. 22996375 LncRNADisease
liver cancer N/A N/A N/A regulation Control of imprinting. Containing miRNA miR-675. 22996375 LncRNADisease
lung cancer N/A N/A N/A regulation Control of imprinting. Containing miRNA miR-675. 22996375 LncRNADisease
tumor N/A N/A N/A epigenetics In recent years, we have extensively investigated the expression of the H19 gene in a number of human cancers and explored the role of H19 RNA in tumor development. 23429271 LncRNADisease
tumor N/A N/A N/A expression H19, a lncRNA with oncogenic properties, is upregulated in a wide range of tumours. 23660942 LncRNADisease
glioma N/A N/A N/A regulation Epigenetic deregulation of lncRNAs genes is associated with disease 23791884 LncRNADisease
medulloblastoma N/A N/A N/A regulation Epigenetic deregulation of lncRNAs genes is associated with disease 23791884 LncRNADisease
meningioma N/A N/A N/A regulation Epigenetic deregulation of lncRNAs genes is associated with disease 23791884 LncRNADisease
neuroblastoma N/A N/A N/A regulation Epigenetic deregulation of lncRNAs genes is associated with disease 23791884 LncRNADisease
pituitary adenoma N/A N/A N/A regulation Epigenetic deregulation of lncRNAs genes is associated with disease 23791884 LncRNADisease
Prader-Willi syndrome N/A N/A N/A regulation Epigenetic deregulation of lncRNAs genes is associated with disease 23791884 LncRNADisease
bladder cancer N/A N/A N/A expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs 24006935 LncRNADisease
hepatocelluar carcinoma N/A N/A N/A expression Dysregulation and functional roles of lncRNAs in HCC 24183851 LncRNADisease
kidney cancer N/A N/A N/A regulation Tumour suppressor; tumour suppressor host 24373479 LncRNADisease
bladder cancer N/A N/A N/A expression Prognostic marker low-risk marker Oncogene targeted therapy agent 24373479 LncRNADisease
prostate cancer N/A N/A N/A expression Putative susceptibility and diagnostic marker 24373479 LncRNADisease
bladder cancer N/A N/A N/A regulation Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon 24499465 LncRNADisease
liver cancer N/A N/A N/A regulation Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon 24499465 LncRNADisease
lung cancer N/A N/A N/A regulation Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon 24499465 LncRNADisease
tumor N/A N/A N/A regulation Oncofetal H19 RNA promotes tumor metastasis. 24703882 LncRNADisease
hepatocelluar carcinoma N/A N/A N/A expression Overexpression of H19 was found in hepatocellular carcinoma.? 24757675 LncRNADisease
gastric cancer N/A N/A N/A regulation Using real-time RT-PCR, flow cytometry, RNA immunoprecipitation and other methods, Yang et al confirmed that H19 expression in gastric cancer accelerated cell proliferation. 24833871 LncRNADisease
coronary artery disease N/A N/A N/A N/A Re-expression of H19 has been observed in patients with atherosclerosis. Common polymorphisms of H19 are associated with the risk and severity of CAD in a Chinese population. 25772106 LncRNADisease
Beckwith-Wiedemann syndrome N/A N/A N/A epigenetics Allelic methylation of H19 and IGF2 in the Beckwith-Wiedemann syndrome. 7987305 LncRNADisease
cervical cancer N/A N/A N/A mutation High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. 8570220 LncRNADisease
breast adenocarcinomas N/A breast adenocarcinoma stromal cells up-regulated expression An up-regulation of the h19 gene is significantly correlated with the tumor values and the presence of both estrogen and progesterone receptors 9811352
bladder cancer PCR-RFLP etc. blood differential expression mutation A significantly decreased risk of bladder cancer was found for the rs2839698 TC genotype but not for CC homozygotes.The rs2839698 TC genotype was especially associated with a reduced risk of developing non-muscle-invasive disease. Borderline significantly 18262338 LncRNADisease Lnc2Cancer
meningioma qPCR etc. meningioma tissue differential expression N/A In total, 24 meningiomas of WHO grade I, II and III were analysed. 15 meningiomas (63%) were informative for the ApaI polymorphism in the IGF2 gene. Monoallelic expression (MAE) for IGF2 was found in 11 out of 15 tumours (73%) which is in contrast to the lack of imprinting status of IGF2 in leptomeninges. Ten cases (42%) were heterozygous for the H19 gene and biallelic expression was found in 3 out of 10 meningiomas (30%). These results indicate that modulation of the imprinting status of IGF2 and H19 may play an important role for the development of meningiomas. 10738131 Lnc2Cancer
colorectal cancer qPCR etc. CRC tissue up-regulated N/A LOI of IGF2 correlated strongly with biallelic hypermethylation of a core of five CpG sites in the insulator region of IGF2/H19, which is a known CTCF-binding element. As this methylation-dependent LOI was present in both tumors and normal colonic mucosa, it is possible that hypermethylation creates a field defect predisposing to cancer. 11120891 Lnc2Cancer
germ cell tumor qPCR etc. germ cell tumor tissue differential expression epigenetics IGF2/H19 methylation status in GCTs might reflect preservation of the physiologic imprinting erasure in PGCs rather than a loss of imprinting in a sense that is accepted for somatic tumors. 16001432 LncRNADisease Lnc2Cancer
breast cancer qPCR etc. cell lines (MCF10A, RPMI 1640, DMEM H21 etc.) up-regulated expression Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. 16707459 LncRNADisease Lnc2Cancer
lung cancer qPCR etc. cell lines (MCF10A, RPMI 1640, DMEM H21 etc.) up-regulated expression Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. 16707459 LncRNADisease Lnc2Cancer
breast cancer qPCR etc. breast cancer tissue differential expression mutation rs2107425 (C>T) near H19 was significantly associated with shorter metastasis-free survival in uni- and multi-variate analysis , with the more aggressive minor allele displaying a recessive trait. 21748294 LncRNADisease Lnc2Cancer
gastric cancer qPCR etc. gastric cancer tissue, cell lines (HGC27) up-regulated N/A Plasma H19 levels were significantly higher in patients than in healthy controls (p=0.029). Circulating lncRNAs can be detectable in plasma, and the detection of circulating lncRNAs may provide new complementary tumor markers for gastric cancer. 23898077 Lnc2Cancer
hepatocelluar carcinoma qPCR etc. cell lines (SMMC-7721, HepG2) up-regulated N/A Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). 24063685 Lnc2Cancer
prostate cancer qPCR etc. cell lines ((Du-145, PC-3) down-regulated N/A Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). 24063685 Lnc2Cancer
lung cancer qPCR etc. cell lines (A549) down-regulated N/A Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). 24063685 Lnc2Cancer
gastric cancer qPCR etc. gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) up-regulated expression After validating in 20 pairs of tissues and plasma in training set, H19 was selected for further analysis in another 70 patients and 70 controls. Plasma level of H19 was significantly higher in GC patients compared with normal controls. 26096073 Lnc2Cancer
liver cancer qPCR etc. hepatocellular carcinoma tissue up-regulated expression LncRNA profiling revealed that CD90+ cells were enriched in lncRNA H19, and released this through exosomes.Experiments of gain and loss of function of H19 showed that this LncRNA plays an important role in the exosome-mediated phenotype of endothelial cells. Moreover, we suggest the lncRNA H19 as a putative therapeutic target in hepatocellular carcinoma. 26272696 Lnc2Cancer
medulloblastoma qPCR etc. fetal cerebella tissue, cell lines (MEB-MED, D283 etc.) differential expression expression Loss of imprinting of H19 occurred in 0 out of 4 informative fetal cerebella, 0 out of 1 informative adult cerebellum, 4 out of 8 informative medulloblastomas, and 1 out of 4 informative cell lines. The biallelic expression of H19 was only partial in two medulloblastomas, however, with one allele being significantly weaker than the other. 8957451 Lnc2Cancer
breast cancer qPCR, ISH etc. MDA-MB-231 cell line up-regulated expression Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. 12419837 LncRNADisease Lnc2Cancer
bladder cancer qPCR, ISH etc. cell lines (T24P, HT-1376 etc.) up-regulated N/A Bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA. 21162716 LncRNADisease Lnc2Cancer
breast cancer qPCR, knockdown etc. breast cancer tissue, cell lines (MCF7, T47D, BT20 etc.) up-regulated expression the transcript is stabilized in breast cancer cells and overexpressed in human breast tumors.91H expression is upregulated in breast cancer. 18794369 LncRNADisease Lnc2Cancer
ovarian cancer qPCR, knockdown etc. cell lines (PC3, C2C12 etc.) up-regulated expression H19 RNA was detected in 90% of patients with OCAF (Ovarian cancer ascites fluid ) as determined by ISH. Intratumoral injection of DTA-H19 into ectopically developed tumors caused 40% inhibition of tumor growth. 19656414 LncRNADisease Lnc2Cancer
gastric cancer qPCR, knockdown etc. gastric cancer tissue, cell lines MGC-803, SGC-7901, GES-1) up-regulated regulation c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. 24671855 LncRNADisease Lnc2Cancer
esophageal squamous cell carcinoma qPCR, knockdown etc. ESCC tissue, cell lines (TE-1 ,Eca-109) down-regulated regulation Long non-coding RNA 91H contributes to the occurrence and progression of esophageal squamous cell carcinoma by inhibiting IGF2 expression. 24706416 LncRNADisease Lnc2Cancer
colorectal cancer qPCR, knockdown etc. CRC tissue, cell lines ( HCT8, HT29, HCT116, SW620 etc.) up-regulated regulation 91H was significantly overexpressed in cancerous tissue and CRC cell lines compared with adjacent normal tissue and a normal human intestinal epithelial cell line. Moreover, 91H overexpression was closely associated with distant metastasis and poor prognosis in patients with CRC, except for CNV of 91H. Multivariate analysis indicated that 91H expression was an independent prognostic indicator, as well as distant metastasis. 91H played an important role in the molecular etiology of CRC and might be regarded as a novel prognosis indicator in patients with CRC. 25058480 Lnc2Cancer
skin cancer qPCR, lncRNA array analysis cultured mouse keratinocytes after deleting the vitamin D receptor (VDR) (∼90%) vs. control cells up-regulated expression Several well-known oncogenes, including H19, HOTTIP and Nespas, are significantly increased (6.3-1.8-fold), whereas tumor suppressors (Kcnq1ot1, lincRNA-p21) are decreased (up to 50-70%) in VDR deleted keratinocytes. 24342142
bladder cancer qPCR, Luciferase reporter assay, in vitro knockdown, RIP etc. bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) up-regulated regulation Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. 23354591 LncRNADisease Lnc2Cancer
gastric cancer qPCR, Luciferase reporter assays, in vitro knockdown, RIP etc. gastric cancer tissue,cell lines (AGS, MKN45, MGC803, SGC7901, GES-1 etc.) up-regulated N/A We demonstrated that H19 levels were markedly increased in gastric cancer cells and gastric cancer tissues compared with normal controls. Moreover, ectopic expression of H19 increased cell proliferation, whereas H19 siRNA treatment contributed to cell apoptosis in AGS cell line. We further verified that H19 was associated with p53, and that this association resulted in partial p53 inactivation. 22776265 Lnc2Cancer
gastric cancer qPCR, Luciferase reporter assays, knockdown etc. gastric cancer tissue up-regulated interaction H19 expression was found to be inversely correlated to miR-141 expression in gastric cancer cells and tissues. H19 promotes malignancy including proliferation and invasion whereas miR-141 suppresses malignancy in human cancer cells. MiR-141 binds to H19 in a sequence specific manner, and suppresses H19 expression and functions including proliferation and invasion. MiR-141 could also regulate H19 target genes and miR-141 inhibitor restores H19 siRNA function, while H19 regulates miR-141 target gene ZEB1 26160158 Lnc2Cancer
non-small cell lung cancer qPCR, Luciferase reporter assays, knockdown, ChIP etc. NSCLC cell lines (A549, SPCA1) up-regulated interaction The higher expression of H19 was positively correlated with advanced tumor-node-metastasis (TNM) stage and tumor size. Multivariate analyses found that H19 expression could serve as an independent prognostic factor for overall survival of NSCLC. Moreover, chromatin immunoprecipitation (ChIP) assays revealed that H19 was a direct transcriptional target of c-Myc. And, knockdown of H19 significantly inhibited NSCLC cell proliferation both in vitro and in vivo. 26482621 Lnc2Cancer
glioblastoma qPCR, Neurosphere Formation assay etc. glioblastoma tissue, cell lines (U87, U373) up-regulated expression H19 is significantly overexpressed in glioblastoma tissues, and the level of expression was associated with patient survival. In the subsequent investigations, the authors found that overexpression of H19 promotes glioblastoma cell invasion and angiogenesis in vitro. Interestingly, H19 was also significantly overexpressed in CD133+ glioblastoma cells, and overexpression of H19 was associated with increased neurosphere formation of glioblastoma cells. 26274999 Lnc2Cancer
breast cancer qPCR, Northern blot etc. breast cancer tissue differential expression expression H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-neoplastic WAP-CRD-BP mammary tissue. 14729626 LncRNADisease Lnc2Cancer
colon cancer qPCR, Northern blot, ISH etc. CRC tissue up-regulated locus Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. 19926638 LncRNADisease Lnc2Cancer
colorectal cancer qPCR, RFLP-PCR etc. CRC tissue up-regulated N/A The results of the present study suggest that LOI of IGF2 is important in the carcinogenesis of CRC. Hypomethylation of the sixth CTCF-binding site in the DMR of IGF2/H19 is linked to LOI and the common IGF2-H19 enhancer competition model for IGF2 imprinting does not apply to human CRC. 22427002 Lnc2Cancer
bladder cancer qPCR, Western blot etc. bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) up-regulated regulation Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. 23399020 LncRNADisease Lnc2Cancer
chronic myeloid leukemia qPCR, Western blot etc. cell lines (K562) up-regulated N/A We observed that H19 was highly expressed in Bcr-Abl-expressing primary CML cells derived from 4 patients, and imatinib treatment greatly decreased the expression of H19 in these cells but not in normal control cells. Loss of either Bcr-Abl expression or Abl kinase activity caused decrease of c-Myc levels with simultaneously reduced levels of H19. Furthermore, we demonstrated that depletion of c-Myc alone in K562 cells significantly decreased the level of H19, suggesting that H19 is expressed in a c-Myc dependent manner in K562 leukemic cells. 24685695 Lnc2Cancer
prostate cancer qPCR, Western blot etc. cell lines (P69, M12) down-regulated N/A In this study, we found that long non-coding RNA H19 (H19) and H19-derived microRNA-675 (miR-675) were significantly downregulated in the metastatic prostate cancer cell line M12 compared with the non-metastatic prostate epithelial cell line P69. Upregulation of H19 in P69 and PC3 cells significantly increased the level of miR-675 and repressed cell migration; however, ectopic expression of H19 in M12 cells could not increase the level of miR-675 and therefore had no effect on cell migration. 24988946 Lnc2Cancer
bladder cancer qPCR, Western blot etc. bladder cancer tissue, cell lines (5637, UMUC-3, EJ) up-regulated interaction YAP1 and H19 expression levels were markedly elevated in bladder cancer tissues and cells, and H19 expression was found to be significantly associated with YAP1 expression. YAP1 and H19 were overexpressed were associated with poorer clinicopathologic prognosis. In addition, YAP1 was found to enhance H19 expression, whereas H19 had no significant effect on YAP1 expression in bladder cancer cells. 26163939 Lnc2Cancer
gastric cancer qPCR, Western blot, knockdown etc. gastric cancer tissue, cell lines (AGS, MGC803 etc.) up-regulated N/A The expression levels of H19 and miR-675 in five gastric cancer cell lines were correlated with each other (r = 0.9910, P = 0.0315, data not shown). We next assessed the correlation of miR-675 and H19 expression in 24 human gastric cancer tissues. The expression of H19 and miR-675 in gastric cancer tissues was correlated with each other (r = 0.8214, P < 0.01). 24388988 Lnc2Cancer
hepatocelluar carcinoma qPCR, Western blot, knockdown etc. cell lines (HepG2) up-regulated N/A We found that AFB1 could up-regulate the expression of H19 and promote cell growth and invasion by hepatocellular carcinoma HepG2 cells. AFB1 induced the expression of E2F1 and its knock-down could down-regulate H19 expression and suppress cell growth and invasion in hepatocellular carcinoma HepG2 cells. E2F1 over-expression could up-regulate H19 expression and promote cell growth and invasion, with binding to the H19 promoter being demonstrated by chromatin immunoprecipitation assays. 24761865 Lnc2Cancer
pancreatic ductal adenocarcinoma qPCR, Western blot, knockdown etc. pancreatic cancer tissue, cell lines (PANC-1, SW1990, AsPC-1, BxPC-3, CFPAC-1 etc.) up-regulated N/A The levels of H19 was overexpressed in PDAC and was upregulated remarkably in primary tumors which subsequently metastasized, compared to those did not metastasis. H19 promoted PDAC cell invasion and migration. An important role of H19 in regulating metastasis of PDAC and provides some clues for elucidating the lncRNAmiRNA functional network in cancer. 24920070 Lnc2Cancer
hepatocelluar carcinoma qPCR, Western blot, knockdown etc. cell lines (Huh-7, MHCC-97H, HepG2 etc.) up-regulated N/A The expression levels of LncRNAH19 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells as compared with the control group. Inhibition of LncRNAH19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3β/Cdc25A signaling pathway. 24939300 Lnc2Cancer
breast cancer qPCR, Western blot, knockdown etc. breast cancer tissue, cell lines (MCF-7, MDA-MB-231) up-regulated N/A H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells; H19 lncRNA was much higher in estrogen receptor (ER)-positive MCF-7 breast cancer cells than in ER-negative MDA-MB-231 cells 25846769 LncRNADisease Lnc2Cancer
esophageal cancer qPCR, Western blot, knockdown etc. esophageal cancer tissue, cell lines (TE-1, TE-10, Eca-1, Eca-109, KYSE1170) up-regulated expression The expression of H19 was significantly increased and associated with tumor depth and metastasis in 133 EC samples. In addition, it was identified that an upregulation of H19 induced epithelial-to-mesenchymal transition. In conclusion, H19 has a significant role in the development of EC and may serve as a potential prognostic marker and therapeutic target for EC. 26171017 Lnc2Cancer
ovarian cancer qPCR, Western blot, knockdown etc. ovarian cancer tissues and adjacent normal tissues, cell lines (SKOV3, OV90, TOV112D, ES2) up-regulated expression Our results demonstrated that that H19 silencing inhibited OV90 and SKOV3 OC cell proliferation in vitro. Further investigation into the mechanisms responsible for the growth inhibitory effects by H19 silencing revealed that its knockdown resulted in the induction of cell cycle arrest and apoptosis through certain cell cycle-related and apoptosis-related proteins 26617715 Lnc2Cancer
colorectal cancer qPCR, Western blot, Luciferase reporter assay, RIP etc. CRC tissue, cell lines (SW620, HCT-116) up-regulated interaction We found that H19 was highly expressed in mesenchymal-like cancer cells and primary CRC tissues. H19 modulated the expression of multiple genes involved in EMT by acting as a competing endogenous RNA, which may build up the missing link between the regulatory miRNA network, EMT progression and accelerates in vivo and in vitro tumor growth. 26068968 Lnc2Cancer
gastric cancer qPCR, Western blot, Luciferase reporter assays, knockdown etc. gastric cancer tissue, cell lines (SGC7901, MKN45, MKN-28 etc.) up-regulated expression Overexpression of?lncRNA?H19 enhances carcinogenesis and metastasis of gastric cancer. 24810858 LncRNADisease Lnc2Cancer
bladder cancer qPCR, Western blot, Luciferase reporter assays, knockdown etc. bladder cancer tissues, cell lines (RT4, HT-1376, 5637, 253J, TCCSUP, T24,and J82) up-regulated interaction We found that miR-675 expression levels were remarkably increased in bladder cancer tissues as compared with adjacent noncancerous tissues or normal bladder tissue from health donors; moreover, enhanced miR-675 expression was also observed in bladder cancer cell lines. Ectopic expression of H19 significantly increased bladder cancer cell proliferation and miR-675 expression in vitro 26198047 Lnc2Cancer
hepatocelluar carcinoma qPCR, Western bolt, Northern bolt, in vitro knockdown, RIP etc. HCC tissue, cell lines(SMMC7721, HCCLM3) down-regulated regulation Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. 23222811 LncRNADisease Lnc2Cancer
clear cell renal cell carcinoma qRT-PCR, siRNA clear cell renal carcinoma (ccRCC) tissues and renal cancer cell lines up-regulated expression lncRNA H19 might be considered as a potential prognostic indicator and a target for gene therapy of ccRCC. 25866221
gastric cancer real-time quantitative polymerase chain reaction (qPCR) assay gastric cancer (GC) tissues up-regulated expression H19 might serve as a promising biomarker for early detection and prognosis prediction of GC. 26774144
breast cancer RNA CISH etc. breast cancer tissue up-regulated expression HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. 26323944 Lnc2Cancer
non-small cell lung cancer RT-PCR, luciferase reporter assay, Chromosome immune coprecipitation (ChIP), disturbing and overexpressing the expression of H19, flow cytometry NSCLC tissues and cells, the adjacent tissues and normal cells up-regulated interaction lncRNA H19, which is induced by c-Myc, is up-regulated in NSCLC. H19 influences the mitotic progression of NSCLC cell lines. 26722426
Wilms' tumor Southern blot, Northern blot etc. Wilms' tumor tissue differential expression epigenetics Gain of methylation at the H19 DMR is an early event in Wilms' tumorigenesis that is independent of chromosomal losses. 16179496 LncRNADisease Lnc2Cancer
gastric cancer stratified analyses gastric cancer samples up-regulated mutation We genotyped four lncRNA H19 single nucleotide polymorphisms (SNPs)(rs217727 C > T, rs2839698 C > T, rs3741216 A > T, rs3741219 T > C) in 500 GC patients and 500 healthy controls. These findings suggest that lncRNA H19 SNPs may contribute to susceptibility to GC. 25944697
 


Function (not disease relevant)
Methods Sample/condition Expression pattern Dysfunction type Description PMID Source
ChIP-seq analysis fetal liver cells N/A interaction Long noncoding RNA H19 inhibits the proliferation of fetal liver cells and the Wnt signaling pathway. 26801864
knockdown N/A N/A interaction H19 knockdown activates SAHH, leading to increased DNMT3B-mediated methylation of an lncRNA-encoding gene Nctc1 within the Igf2-H19-Nctc1 locus. Methylation changes at numerous gene loci consistent with SAHH modulation by H19. 26687445
knockdown gallbladder cancer cell, GBC-SD and NOZ cells up-regulated interaction H19/miR-194-5p/AKT2 axis regulatory network might modulate cell proliferation in GBC. H19 elevation was significantly associated with tumor size. Cell proliferation decreased significantly after knockdown of H19 in GBC-SD and NOZ cells and after knockdown of AKT2 in NOZ cells. the S phase were significantly decreased after knockdown of H19 in NOZ cells but significantly elevated after overexpression of H19 in GBC-SD cells. 26803515
lncRNA microarray human bone marrow mesenchymal stem cells (MSCs) up-regulated expression The results showed that the two up-regulated lncRNAs are likely to play important roles in osteogenic differentiation process。 25634249
LncRNA microarray Dermal papilla (DP) cells up-regulated expression RP11-766N7.3, H19 and HOTAIR are specific lncRNAs that were aberrantly expressed in DP cells and played an important role in regulating Wnt signaling 25285630
N/A undifferentiated multipotent mesenchymal C2C12 cells N/A expression H19 operates as a molecular scaffold that facilitates effective association of KSRP with myogenin and otherlabile transcripts, and we propose that H19 works with KSRP to optimize an AKT-regulated posttranscriptional switch that controls myogenic differentiation. 25385579
N/A intestinal epithelial cell up-regulated N/A controlling the intestinal epithelial barrier function by serving as a precursor for microRNA 675 (miR-675 26884465
N/A N/A N/A interaction Human h19 rna contains four attachment sites for the oncofetal igf-ii mrna-binding protein (imp) 10875929
N/A N/A N/A expression Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. 15645136 LncRNADisease
N/A N/A N/A N/A N/A 18587395
overexpression, knockdown N/A up-regulated interaction The novel pathway H19/miR-675/TGF-β1/Smad2/HDAC regulates osteogenic differentiation of hMSCs and may serve as a potential target for enhancing bone formation in vivo. 26417995
RIP assays combined with luciferase reporter assays osteogenesis in hMSCs up-regulated N/A lncRNA H19 modulates Wnt/β-catenin pathway 26853553
RNA interference human K562 leukemia cells N/A interaction Imp-3 protein associates with igf-ii leader-3 and leader-4 mrnas and h19 rna 15753088
transfect two embryonal tumour cell lines, RD and G401 N/A expression Two embryonal tumour cell lines, rd and g401, showed growth retardation and morphological changes when transfected with an h19 expression construct. 7692308
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
SERPINE1 RNA-RNA co-expression Half-sbsRNA1 siRNA increased the levels of SERPINE1 and FLJ21870 mRNAs to 2-to-4.5-fold above normal. 10738131
IMP RNA-Protein binding Human h19 rna contains four attachment sites for the oncofetal igf-ii mrna-binding protein (imp) 10875929
IMP-3 RNA-Protein regulation Imp-3 protein associates with igf-ii leader-3 and leader-4 mrnas and h19 rna 15753088
miR-675 RNA-RNA co-expression Recently, it was found that the H19 RNA is host to an exonic microRNA, miR-675, which, as a result, is also imprinted and maternally expressed. 19239885 LncRNADisease
c-myc DNA-TF regulation H19 has been linked to the oncogene, c-myc, which positively regulates its expression in diverse cell types including T98G human glioblastoma cells. 20380817 LncRNADisease
p53 DNA-TF regulation H19 has been linked to the tumor suppressor, p53, which negatively regulates its expression. 20380817 LncRNADisease
GLI1 DNA-TF regulation H19 is a target of the GLI1 transcription factor, which mediates SHH signaling and is amplified more than 50-fold in human gliomas. 20380817 LncRNADisease
SHH DNA-TF regulation H19 is a target of the GLI1 transcription factor, which mediates SHH signaling and is amplified more than 50-fold in human gliomas. 20380817 LncRNADisease
E2F1 RNA-Protein regulation H19 transcription is positively regulated by the cell cycle regulatory factor, E2F1, during the S-phase of growth-stimulated cells. 20380817 LncRNADisease
Igf2 RNA-RNA co-expression Complex functions, influences growth by down-regulating a number of imprinted genes including Igf2, also implicated as both a tumour suppressor and an oncogene. 21256239 LncRNADisease
CTCF1 RNA-RNA co-expression Significant reductions at the H19 CTCF 1 and CTCF 2 binding sites were observed in the offspring of ethanol-treated sires, which was significantly correlated with reduced weight at postnatal days 35-42 (p? 22395465 LncRNADisease
CTCF2 RNA-RNA co-expression Significant reductions at the H19 CTCF 1 and CTCF 2 binding sites were observed in the offspring of ethanol-treated sires, which was significantly correlated with reduced weight at postnatal days 35-42 (p<=0.05). 22395465 LncRNADisease
CTCF3 RNA-RNA co-expression There is a CTCF-binding site (CTCF3) in the imprinting control region (ICR) upstream of H19. 22395465 LncRNADisease
IGF2 RNA-Protein regulation H19 is an imprinted maternally expressed gene influencing IGF2 expression, whose transcript is a long noncoding (lnc) RNA of unknown biological function harboring the miR-675. 22527881
H19 transcript can counteract 91H-mediated Igf2 activation RNA-RNA regulation A large excess of the H19 transcript can counteract 91H-mediated Igf2 activation. 22662250
Igf2 RNA-Protein regulation Ectopic expression of the mouse 91H RNA can up-regulate Igf2 expression in trans 22662250
let-7 family of microRNAs RNA-RNA binding Vertebrate H19 harbors both canonical and noncanonical binding sites for the let-7 family of microRNAs, which plays important roles in development, cancer, and metabolism. 24055342
H1.3 RNA-Protein regulation H1.3dramatically inhibits H19 expression, which contributes to the suppression of epithelial ovarian carcinogenesis. 25205099
K homology-type splicing regulatory protein (KSRP) RNA-Protein binding KSRP directly binds to H19 in the cytoplasm of undifferentiated multipotent mesenchymal C2C12 cells 25385579
miR-138 and miR-200a RNA-RNA regulation by using bioinformatics study and RNA immunoprecipitation combined with luciferase reporter assays, we demonstrated that H19 functioned as a competing endogenous RNA (ceRNA) for miR-138 and miR-200a, antagonized their functions and led to the de-repression of their endogenous targets Vimentin, ZEB1, and ZEB2, all of which were core marker genes for mesenchymal cells 26068968
MiR-141 RNA-RNA binding MiR-141 binds to H19 in a sequence specific manner, and suppresses H19 expression and functions including proliferation and invasion. MiR-141 could also regulate H19 target genes and miR-141 inhibitor restores H19 siRNA function, while H19 regulates miR-141 target gene ZEB1. 26160158
Yes-associated protein 1 (YAP1) RNA-Protein co-expression H19 expression was found to be significantly associated with YAP1 expression. H19, at least in part, is induced by YAP1 overexpression. 26163939
miR-675 RNA-RNA regulation Ectopic expression of H19 significantly increased bladder cancer cell proliferation and miR-675 expression in vitro. 26198047
histone deacetylase (HDAC) 4/5 RNA-DNA regulation H19/miR-675 downregulated the mRNA and protein levels of histone deacetylase (HDAC) 4/5, and thus increased osteoblast marker gene expression. 26417995
transforming growth factor-β1 (TGF-β1) RNA-DNA regulation H19/miR-675 inhibited mRNA and protein expression of transforming growth factor-β1 (TGF-β1). 26417995
c-Myc RNA-Protein regulation H19 was a direct transcriptional target of c-Myc. 26482621
S-adenosylhomocysteine hydrolase (SAHH) RNA-Protein binding The developmentally regulated H19 lncRNA binds to and inhibits S-adenosylhomocysteine hydrolase (SAHH), the only mammalian enzyme capable of hydrolysing S-adenosylhomocysteine (SAH) 26687445
c-Myc DNA-DNA regulation The activity of the promoter of H19 was strengthened by c-Myc. 26722426
miR-107 RNA-RNA regulation The expression of miR-107 increased or decreased with the overexpression and knockdown of H19, respectively. The number of cells in G2/M stage decreased significantly with the knockdown of H19 and miR-107 compared with the control group. 26722426
heterogeneous nuclear ribonucleoprotein (hnRNP) U and actin RNA-Protein regulation H19 may inhibit the proliferation of fetal liver cells by blocking the interaction between heterogeneous nuclear ribonucleoprotein (hnRNP) U and actin, which results in gene transcriptional repression. 26801864
AKT2 RNA-RNA co-expression The RNA levels of H19 and AKT2 were positively correlated. 26803515
miR-141 and miR-22 RNA-RNA binding H19 functioned as an miRNA sponge for miR-141 and miR-22, both of which were negative regulators of osteogenesis and Wnt/β-catenin pathway. 26853553
HuR RNA-Protein regulation H19 interacts with HuR and regulates the intestinal epithelial barrier function via the H19-encoded miR-675 by altering ZO-1 and E-cadherin expression posttranscriptionally. 26884465
miR-675 RNA-RNA regulation H19 plays an important role in controlling the intestinal epithelial barrier function by serving as a precursor for microRNA 675 (miR-675). H19 overexpression increased the cellular abundance of miR-675, which in turn destabilized and repressed the translation of mRNAs encoding tight junction protein ZO-1 and adherens junction E-cadherin, resulting in the dysfunction of the epithelial barrier. 26884465
RUNX1 RNA-DNA regulation Overexpression of H19 or miR-675 significantly decreased RUNX1 expression in AGS cells, and knockdown of H19 or miR-675 enhanced RUNX1 expression. 26931432
miR-675 RNA-RNA regulation The expression of miR-675 was positively correlated with H19 in patients with gastric cancer. 26931432
eIF4A3 RNA-Protein binding eIF4A3 as an RNA-binding protein that binds to H19. Combining eIF4A3 with H19 obstructed the recruitment of eIF4A3 to the cell-cycle gene mRNA. 26989025
EZH2 RNA-DNA regulation H19 regulated EZH2 expression by suppressing the activity of miR-630, which is a repressor of EZH2 and interacts with H19 in a sequence-specific manner. 27040767
miR-630 RNA-RNA regulation H19 regulated EZH2 expression by suppressing the activity of miR-630, which is a repressor of EZH2 and interacts with H19 in a sequence-specific manner. 27040767
CaMKIIδ RNA-Protein regulation CaMKIIδ was a direct target of miR-675 and partially mediated the effect of H19 on cardiomyocyte hypertrophy. 27084844
miR-675 RNA-RNA regulation H19 encoded miR-675. 27084844